CR11223A - Compuestos de biciclolactama sustituida - Google Patents
Compuestos de biciclolactama sustituidaInfo
- Publication number
- CR11223A CR11223A CR11223A CR11223A CR11223A CR 11223 A CR11223 A CR 11223A CR 11223 A CR11223 A CR 11223A CR 11223 A CR11223 A CR 11223A CR 11223 A CR11223 A CR 11223A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- bicycolactama
- substituted
- compositions
- document
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La invencion proporciona compuestos de formula (1) y la sal farmaceuticamente aceptable de los mismos, en el que R1, R2, R3, R4, R5a, R5b, R5c, R5d, Q, A, Z y R7 son como se ha descrito en este documento; composiciones de los mismos; y usos de los mismos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95350707P | 2007-08-02 | 2007-08-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR11223A true CR11223A (es) | 2010-02-04 |
Family
ID=39926534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR11223A CR11223A (es) | 2007-08-02 | 2010-01-18 | Compuestos de biciclolactama sustituida |
Country Status (34)
Country | Link |
---|---|
US (2) | US20090036425A1 (es) |
EP (1) | EP2185567B1 (es) |
JP (1) | JP4629808B2 (es) |
KR (1) | KR20100032443A (es) |
CN (1) | CN101772504A (es) |
AP (1) | AP2010005163A0 (es) |
AR (1) | AR067780A1 (es) |
AT (1) | ATE502948T1 (es) |
AU (1) | AU2008281545B2 (es) |
BR (1) | BRPI0815067A2 (es) |
CA (1) | CA2695291C (es) |
CL (1) | CL2008002227A1 (es) |
CO (1) | CO6251365A2 (es) |
CR (1) | CR11223A (es) |
CY (1) | CY1111628T1 (es) |
DE (1) | DE602008005757D1 (es) |
DK (1) | DK2185567T3 (es) |
DO (1) | DOP2010000046A (es) |
EA (1) | EA201000050A1 (es) |
EC (1) | ECSP109932A (es) |
ES (1) | ES2361716T3 (es) |
HN (1) | HN2008001191A (es) |
HR (1) | HRP20110335T1 (es) |
MA (1) | MA31580B1 (es) |
PA (1) | PA8791601A1 (es) |
PE (1) | PE20090897A1 (es) |
PL (1) | PL2185567T3 (es) |
PT (1) | PT2185567E (es) |
SI (1) | SI2185567T1 (es) |
TN (1) | TN2010000053A1 (es) |
TW (1) | TWI356059B (es) |
UA (1) | UA94833C2 (es) |
WO (1) | WO2009016462A2 (es) |
ZA (1) | ZA201000255B (es) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ555683A (en) | 2004-12-14 | 2010-09-30 | Astrazeneca Ab | Oxadiazole derivatives as dgat inhibitors |
JP2009520786A (ja) | 2005-12-22 | 2009-05-28 | アストラゼネカ アクチボラグ | Dgat阻害剤として使用するためのピリミド−[4,5−b]−オキサジン |
PL2402319T3 (pl) | 2006-03-31 | 2018-02-28 | Novartis Ag | Inhibitory DGAT |
US8084478B2 (en) | 2006-05-30 | 2011-12-27 | Asstrazeneca Ab | Substituted 5- phenylamino- 1, 3, 4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase |
KR20090024811A (ko) | 2006-06-23 | 2009-03-09 | 아보트 러보러터리즈 | 히스타민 h3 수용체 조절제로서의 사이클로프로필 아민 유도체 |
US9108948B2 (en) * | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
AR066169A1 (es) | 2007-09-28 | 2009-07-29 | Novartis Ag | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat |
TW201038580A (en) * | 2009-02-02 | 2010-11-01 | Pfizer | 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives |
WO2010089685A1 (en) * | 2009-02-03 | 2010-08-12 | Pfizer Inc. | 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives |
EP2393811A1 (en) * | 2009-02-04 | 2011-12-14 | Pfizer Inc. | 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives |
EP2805951B1 (en) | 2009-03-20 | 2018-03-14 | Metabasis Therapeutics, Inc. | Inhibitors of diacylglycerol o-acyltransferase 1 (DGAT-1) and uses thereof |
US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
RU2524341C2 (ru) | 2010-03-19 | 2014-07-27 | Пфайзер Инк. | Производные 2,3-дигидро-1н-инден-1-ил-2,7-диазаспиро[3.5]нонана и их применение в качестве антагонистов или обратных агонистов грелинового рецептора |
WO2011121350A1 (en) | 2010-04-01 | 2011-10-06 | Astrazeneca Ab | 4 -amino -7,8- dihydropyrimido [5, 4 - f] [1, 4] oxazepin- 5 ( 6h) - one based dgat1 inhibitors |
WO2012037258A1 (en) | 2010-09-16 | 2012-03-22 | Abbott Laboratories | Processes for preparing 1,2-substituted cyclopropyl derivatives |
CN103189377B (zh) | 2010-10-29 | 2015-02-25 | 辉瑞大药厂 | N1/n2-内酰胺乙酰辅酶a羧化酶抑制剂 |
WO2012112364A1 (en) * | 2011-02-14 | 2012-08-23 | Merck Sharp & Dohme Corp. | Lactam derivatives as dgat-1 inhibitors |
WO2012122075A1 (en) * | 2011-03-08 | 2012-09-13 | Merck Sharp & Dohme Corp. | Lactam derivatives as dgat-1 inhibitors |
PT2699576E (pt) | 2011-04-22 | 2016-03-09 | Pfizer | Derivados de pirazoloespirocetona para utilização como inibidores de acetil-coa carboxilase |
MX361350B (es) | 2011-05-10 | 2018-12-04 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como moduladores del canal de sodio. |
US8859536B2 (en) * | 2011-05-20 | 2014-10-14 | Glaxosmithkline Intellectual Property (No.2) Limited | Compounds as diacylglycerol acyltransferase inhibitors |
NO3175985T3 (es) | 2011-07-01 | 2018-04-28 | ||
TW201837023A (zh) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
WO2013011402A1 (en) | 2011-07-15 | 2013-01-24 | Pfizer Inc. | Gpr 119 modulators |
MX2014000855A (es) | 2011-07-22 | 2014-04-30 | Pfizer | Moduladores receptores de glucagon de quinolinilo. |
WO2013030713A1 (en) | 2011-08-31 | 2013-03-07 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013068439A1 (en) * | 2011-11-09 | 2013-05-16 | Intervet International B.V. | 4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazepine compounds as dgat1 inhibitors |
WO2013068875A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | 2-thiopyrimidinones |
WO2013119040A1 (en) * | 2012-02-07 | 2013-08-15 | Kainos Medicine, Inc. | Compounds as inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
AU2013245353A1 (en) | 2012-04-06 | 2014-09-25 | Pfizer Inc. | Diacylglycerol acyltransferase 2 inhibitors |
US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
BR112014026910A8 (pt) * | 2012-04-25 | 2018-01-09 | Handok Pharmaceuticals Co Ltd | novo derivado de beta-alanina, seus sais farmaceuticamente aceitáveis, e composições farmacêuticas compreendendo o mesmo como ingrediente ativo. |
CA2872154C (en) | 2012-05-04 | 2016-08-23 | Pfizer Inc. | Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin-2-amine compounds as inhibitors of app, bace1 and bace2 |
KR20150011003A (ko) | 2012-06-20 | 2015-01-29 | 에프. 호프만-라 로슈 아게 | Lpar 길항제로서 치환된 피라졸 화합물 |
CA2882389A1 (en) | 2012-09-20 | 2014-03-27 | Pfizer Inc. | Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
US9550793B2 (en) | 2012-10-03 | 2017-01-24 | Advinus Therapeutics Limited | Spirocyclic compounds, compositions and medicinal applications thereof |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
US9796729B2 (en) | 2012-11-23 | 2017-10-24 | Glaxosmithkline Llc | Compounds as diacylglycerol acyltransferase inhibitors |
NZ630436A (en) | 2012-11-23 | 2016-08-26 | Glaxosmithkline Llc | Novel compounds as diacylglycerol acyltransferase inhibitors |
JP2016502978A (ja) | 2012-12-11 | 2016-02-01 | ファイザー・インク | BACE1の阻害剤としてのヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物 |
JP6162820B2 (ja) | 2012-12-19 | 2017-07-12 | ファイザー・インク | 炭素環式および複素環式置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物 |
WO2014125394A1 (en) | 2013-02-13 | 2014-08-21 | Pfizer Inc. | HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS |
US9233981B1 (en) | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
WO2014140241A1 (en) * | 2013-03-15 | 2014-09-18 | Intervet International B.V. | Pyridine derivatives as dgat-1 inhibitors |
CN104418866B (zh) | 2013-08-23 | 2018-10-16 | 青岛黄海制药有限责任公司 | Dgat1抑制剂及其制备方法和用途 |
EP3055300B1 (en) | 2013-10-09 | 2018-03-07 | Pfizer Inc | Antagonists of prostaglandin ep3 receptor |
AU2015233094B2 (en) | 2014-03-17 | 2017-04-27 | Pfizer Inc. | Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders |
ES2910128T3 (es) | 2014-04-04 | 2022-05-11 | Pfizer | Compuestos de heteroarilo o arilo fusionados con biciclo y su uso como inhibidores de IRAK4 |
MD20160105A2 (ro) | 2014-04-10 | 2017-03-31 | Pfizer Inc. | 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide |
WO2016092413A1 (en) | 2014-12-10 | 2016-06-16 | Pfizer Inc. | Indole and indazole compounds that activate ampk |
WO2016103097A1 (en) | 2014-12-22 | 2016-06-30 | Pfizer Inc. | Antagonists of prostaglandin ep3 receptor |
CR20170498A (es) | 2015-05-05 | 2018-01-26 | Pfizer | 2-tiopirimidinonas |
US10308615B2 (en) | 2015-05-29 | 2019-06-04 | Pfizer Inc. | Heterocyclic compounds as inhibitors of Vanin-1 enzyme |
CA2989456C (en) | 2015-06-17 | 2022-01-04 | Pfizer Inc. | Tricyclic compounds and their use as phosphodiesterase inhibitors |
WO2016203335A1 (en) | 2015-06-18 | 2016-12-22 | Pfizer Inc. | Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors |
BR112018002071A2 (pt) | 2015-08-13 | 2018-09-18 | Pfizer | compostos heteroarílicos ou arílicos fundidos bicíclicos |
DK3341367T3 (da) | 2015-08-27 | 2021-04-12 | Pfizer | Bicyklisk-fusionerede heteroaryl- eller arylforbindelser som irak4-modulatorer |
WO2017037567A1 (en) | 2015-09-03 | 2017-03-09 | Pfizer Inc. | Regulators of frataxin |
WO2017051294A1 (en) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors |
JP2018531924A (ja) | 2015-09-24 | 2018-11-01 | ファイザー・インク | テトラヒドロピラノ[3,4−d][1,3]オキサジン誘導体、およびbace阻害剤としてのその使用 |
JP2018531923A (ja) | 2015-09-24 | 2018-11-01 | ファイザー・インク | N−[2−(2−アミノ−6,6−二置換−4,4a,5,6−テトラヒドロピラノ[3,4−d][1,3]チアジン−8a(8H)−イル)−1,3−チアゾール−4−イル]アミド |
LT3397631T (lt) | 2015-12-29 | 2021-06-10 | Pfizer Inc. | Pakeisti 3-azabiciklo[3.1.0]heksanai kaip ketoheksokinazės inhibitoriai |
EP3484876A1 (en) | 2016-07-14 | 2019-05-22 | Pfizer Inc | Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme |
AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
CN108164548B (zh) * | 2016-12-07 | 2020-09-08 | 四川大学 | 嘧啶并吗啉衍生物及其制备方法和用途 |
WO2019133445A1 (en) | 2017-12-28 | 2019-07-04 | Inception Ibd, Inc. | Aminothiazoles as inhibitors of vanin-1 |
AU2019329884B2 (en) | 2018-08-31 | 2022-01-27 | Pfizer Inc. | Combinations for treatment of NASH/NAFLD and related diseases |
WO2020102575A1 (en) | 2018-11-16 | 2020-05-22 | Inception Ibd, Inc. | Heterocyclic aminothiazoles and uses thereof |
US20220387402A1 (en) | 2019-05-20 | 2022-12-08 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
JP7498199B2 (ja) | 2019-06-28 | 2024-06-11 | ファイザー・インク | 種々の疾患を処置するために有用なbckdk阻害剤としての5-(チオフェン-2-イル)-1h-テトラゾール誘導体 |
TW202115086A (zh) | 2019-06-28 | 2021-04-16 | 美商輝瑞大藥廠 | Bckdk抑制劑 |
TWI771766B (zh) | 2019-10-04 | 2022-07-21 | 美商輝瑞股份有限公司 | 二醯基甘油醯基轉移酶2 抑制劑 |
JP2022058085A (ja) | 2020-02-24 | 2022-04-11 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ |
WO2023026180A1 (en) | 2021-08-26 | 2023-03-02 | Pfizer Inc. | Amorphous form of (s)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tetrahydrofuran-3- yl)pyrimidine-5-carboxamide |
WO2023100061A1 (en) | 2021-12-01 | 2023-06-08 | Pfizer Inc. | 3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure |
WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
WO2024075051A1 (en) | 2022-10-07 | 2024-04-11 | Pfizer Inc. | Hsd17b13 inhibitors and/or degraders |
WO2024118524A1 (en) | 2022-11-28 | 2024-06-06 | Cerevel Therapeutics, Llc | Azaindole compounds and their use as phosphodiesterase inhibitors |
WO2024125602A1 (en) | 2022-12-15 | 2024-06-20 | Gasherbrum Bio, Inc. | Salts and solid forms of a compound having glp-1 agonist activity |
WO2024127297A1 (en) | 2022-12-16 | 2024-06-20 | Pfizer Inc. | 3-fluoro-4-hydroxybenzmide-containing inhibitors and/or degraders and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003062245A1 (fr) * | 2002-01-18 | 2003-07-31 | Kyorin Pharmaceutical Co., Ltd. | Derives de pyrimidine fusionnes bicycliques |
WO2004047755A2 (en) * | 2002-11-22 | 2004-06-10 | Japan Tobacco Inc. | Fused bicyclic nitrogen-containing heterocycles |
AU2005209115A1 (en) * | 2004-01-30 | 2005-08-11 | Japan Tobacco Inc. | Anorectic compounds |
JP2006056881A (ja) * | 2004-07-21 | 2006-03-02 | Takeda Chem Ind Ltd | 縮合環化合物 |
JP2009520786A (ja) * | 2005-12-22 | 2009-05-28 | アストラゼネカ アクチボラグ | Dgat阻害剤として使用するためのピリミド−[4,5−b]−オキサジン |
-
2008
- 2008-07-17 US US12/174,820 patent/US20090036425A1/en not_active Abandoned
- 2008-07-22 ES ES08788942T patent/ES2361716T3/es active Active
- 2008-07-22 JP JP2010518764A patent/JP4629808B2/ja not_active Expired - Fee Related
- 2008-07-22 PL PL08788942T patent/PL2185567T3/pl unknown
- 2008-07-22 PT PT08788942T patent/PT2185567E/pt unknown
- 2008-07-22 AP AP2010005163A patent/AP2010005163A0/en unknown
- 2008-07-22 DE DE602008005757T patent/DE602008005757D1/de active Active
- 2008-07-22 BR BRPI0815067-2A2A patent/BRPI0815067A2/pt not_active IP Right Cessation
- 2008-07-22 UA UAA201001078A patent/UA94833C2/ru unknown
- 2008-07-22 EA EA201000050A patent/EA201000050A1/ru unknown
- 2008-07-22 AT AT08788942T patent/ATE502948T1/de active
- 2008-07-22 CA CA2695291A patent/CA2695291C/en not_active Expired - Fee Related
- 2008-07-22 KR KR1020107002273A patent/KR20100032443A/ko not_active Application Discontinuation
- 2008-07-22 SI SI200830242T patent/SI2185567T1/sl unknown
- 2008-07-22 CN CN200880101674A patent/CN101772504A/zh active Pending
- 2008-07-22 EP EP08788942A patent/EP2185567B1/en active Active
- 2008-07-22 DK DK08788942.4T patent/DK2185567T3/da active
- 2008-07-22 AU AU2008281545A patent/AU2008281545B2/en not_active Expired - Fee Related
- 2008-07-22 WO PCT/IB2008/001963 patent/WO2009016462A2/en active Application Filing
- 2008-07-29 HN HN2008001191A patent/HN2008001191A/es unknown
- 2008-07-29 CL CL2008002227A patent/CL2008002227A1/es unknown
- 2008-07-30 PA PA20088791601A patent/PA8791601A1/es unknown
- 2008-08-01 AR ARP080103360A patent/AR067780A1/es not_active Application Discontinuation
- 2008-08-01 PE PE2008001299A patent/PE20090897A1/es not_active Application Discontinuation
- 2008-08-01 TW TW097129254A patent/TWI356059B/zh not_active IP Right Cessation
-
2009
- 2009-01-22 US US12/357,544 patent/US7718645B2/en not_active Expired - Fee Related
-
2010
- 2010-01-13 ZA ZA2010/00255A patent/ZA201000255B/en unknown
- 2010-01-18 CR CR11223A patent/CR11223A/es not_active Application Discontinuation
- 2010-01-29 TN TNP2010000053A patent/TN2010000053A1/fr unknown
- 2010-02-01 DO DO2010000046A patent/DOP2010000046A/es unknown
- 2010-02-01 CO CO10010179A patent/CO6251365A2/es not_active Application Discontinuation
- 2010-02-02 MA MA32575A patent/MA31580B1/fr unknown
- 2010-02-02 EC EC2010009932A patent/ECSP109932A/es unknown
-
2011
- 2011-05-06 HR HR20110335T patent/HRP20110335T1/hr unknown
- 2011-05-17 CY CY20111100479T patent/CY1111628T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR11223A (es) | Compuestos de biciclolactama sustituida | |
SV2009003281A (es) | Inhibidores espiro cetona de acetil-coa carboxilasa.0 | |
CR8756A (es) | Derivados de acido carboxilico bencimidazolona | |
GT200600134A (es) | Compuestos novedosos de derivados de aminosulfonilo | |
CR8744A (es) | Compuestos terapeuticos | |
UY29486A1 (es) | Compuestos utiles en terapia | |
CR9214A (es) | 2-fenilindoles como antagonistas del receptor de la prostaglandina d2 | |
GT200600518A (es) | Derivados de pirimidina | |
CR10027A (es) | Nuevos derivados de pirrol fusionado | |
GT200400013A (es) | Compuestos de pirazolotriazina y usos de los mismos | |
UY29267A1 (es) | Derivados de piperidina y su uso como agentes antiinflamatorios | |
UY32146A (es) | Derivados de las 5-[4-(1,5-dimetil-1h-pirazol-4-il)-1,2,3-triazol-1-il]-6-metil-nicotinamidas n-(sustituidas) y de las n-{5-[4-(1,5-dimetil-1h-pirazol-4-il)-1,2,3-triazol-1-il]-6-metil-piridin-3-il}-benzamidas sustituidas y composiciones conteniéndolos | |
ECSP088638A (es) | Bencensulfonil-cromano, tiocromano, tetrahidronaftaleno e inhibidores de gamma secretasa relacionados | |
PA8783601A1 (es) | Derivados de piperidina/piperazina | |
UY31071A1 (es) | Derivados heterociclicos sustituidos y su uso farmaceutico y composiciones | |
AR065280A1 (es) | Agentes antiparasitarios | |
UY32463A (es) | Derivados de (1-{[5-(4-halo-2-trifluorometil-fenilamino)piridin-2-ilmetil]-carbamoil -ciclopropil)-amidas de ácidos pirimidin-carboxílicos y similares; sus enantiómeros, sus diastereoisómeros, y sus sales, fisiológicamente tolerables. | |
CR20110381A (es) | Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2 | |
CR9786A (es) | Compuestos de bencimidazol-tiofeno | |
CR11157A (es) | Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica | |
GT200500292A (es) | Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica | |
ECSP088677A (es) | Piperazinas y piperidinas como potenciadores 157 del mglur5 | |
HN2010000330A (es) | DERIVADOS DE INDOL-2-ONA DISUSTITUIDOS EN 3 y SU PREPARACION | |
UY30534A1 (es) | Derivados de 5,6-bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapéutica como antagonistas de los receptores de urotensina ii | |
CO6551705A2 (es) | Derivados de 3.4.4a.10b- tetrahidro-1h-tiopirano-[4.3-c]- isoquinolina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |